Sign in
CRNX Stock Price, Chart, Stats & News
Crinetics Pharmaceuticals, Inc.
Save
Crinetics Pharmaceuticals, Inc. (CRNX) does not currently pay a dividend.
9.00B
Market cap
–
Current P/E
–
Forward P/E
CRNX chart
Fundamentals
Gross margin | 108.47% |
Operating margin | -9534.48% |
Pretax margin | -8581.86% |
Net margin | -8585.18% |
Effective tax rate | -0.04% |
ROA | -40.98% |
ROE | -41.46% |
D/E | 0.05x |
Interest coverage ratio | – |
CRNX valuation
P/E | – |
P/S | 650.45x |
P/B | 3.19x |
P/CF | -8.38x |
P/FCF | -9.19x |
P/OCF | -8.38x |
PEG | 0.73x |
EV multiple | -7.13x |
About
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Similar securities
Based on sector and market capitalization
Report issue